Werewolf Therapeutics, Inc. (HOWL) Revenue History
Annual and quarterly revenue from 2019 to present
HOWL Revenue Over Time (2019–2025)
HOWL Revenue Growth History
1 of 3 years with positive growth- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- +21.6%
- FY2024 revenue growth
- -90.5%
- FY2025 revenue growth
- -100.0%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | -100.0% |
| Q1 2025 | $0 | -100.0% |
| Q4 2024 | $0 | -100.0% |
| Q3 2024 | $0 | -100.0% |
| Q2 2024 | $1.1M | -85.9% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2024)
HOWL's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
HOWL Revenue Analysis (2019–2025)
Current Revenue & Growth
As of June 23, 2026, Werewolf Therapeutics, Inc. (HOWL) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
HOWL's historical revenue data shows various trends over time. Werewolf Therapeutics, Inc.'s highest annual revenue of $19.9 million was recorded in 2023.
Revenue by Segment
HOWL's revenue is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including AGEN (+24.5% YoY), CLDX (-89.2% YoY), and TGTX (+81.3% YoY). Compare HOWL vs AGEN →
HOWL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| HOWLCurrent | $0 | - | - | - | |
 AGEN | $114M | +24.5% | +5.3% | -18.0% | |
 CLDX | $2M | -89.2% | -27.4% | -19160.0% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% |
HOWL Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $-1,634,000 | - | $-60,677,000 | - |
| 2024 | $1.9M | -90.5% | $71K | 3.8% | $-73,594,000 | -3904.2% |
| 2023 | $19.9M | +21.6% | $18.2M | 91.2% | $-40,503,000 | -203.1% |
| 2022 | $16.4M | - | $13.9M | 84.7% | $-56,056,000 | -341.8% |
| 2021 | $0 | - | $0 | - | $-50,087,000 | - |
| 2020 | $0 | - | $-777,000 | - | $-22,404,000 | - |
| 2019 | $0 | - | $-463,000 | - | $-9,936,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
HOWL — Frequently Asked Questions
Quick answers to the most common questions about buying HOWL stock.
Is HOWL's revenue growth accelerating or slowing?
HOWL TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is HOWL's revenue history from 2019 to 2026?
Werewolf Therapeutics, Inc. (HOWL) revenue history spans 2019 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is HOWL's long-term revenue growth rate (CAGR)?
Werewolf Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for HOWL.
Why does HOWL's quarterly revenue fluctuate?
HOWL quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Werewolf Therapeutics, Inc.'s revenue data from 2019 to 2026 shows full historical quarterly detail on this page.
How is HOWL's revenue distributed by segment?
HOWL reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does HOWL's revenue compare to industry peers?
Werewolf Therapeutics, Inc. (HOWL) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.